Skip to main content

SpaceOAR Hydrogel

SpaceOAR creates temporary separation between the prostate and anterior rectal wall to reduce rectal radiation exposure during prostate radiotherapy. SpaceOAR Vue is an iodinated PEG formulation designed for radiographic visibility, including CT; it should not be assigned the same CT appearance as the original noniodinated hydrogel.[1][2]

The February 2026 Vue clearance covers limited component/formulation changes with the same intended use. It does not establish a new clinical-outcome advantage over the earlier device.[1]

Persistence and Imaging​

Manufacturer safety information describes spacing for approximately 12 weeks and absorption around six months, while explicitly noting that complete absorption may take longer. A residual collection is therefore not automatically abnormal at an arbitrary six-month cutoff. Confirm the product, placement date, symptoms and imaging findings.[3]

Evidence​

A phase III trial randomized 222 men receiving conventionally fractionated image-guided IMRT. At a median of three years, rectal toxicity and bowel-quality-of-life outcomes favored the spacer. This supports benefit in that setting, not a guarantee of benefit in every radiation regimen or proof that the device cannot affect oncologic planning or outcomes.[4]

Placement Injury and Reconstructive Relevance​

The spacer is placed transperineally under ultrasound guidance. It can cause important injury if injected into the rectal wall, another unintended tissue plane or a blood vessel. The manufacturer's 2022 safety update emphasizes maintaining needle-tip visualization, aspirating before injection, stopping if blood is aspirated, and stopping immediately if hydrogel is not seen entering the intended perirectal space. Continuing injection into an uncertain plane can produce serious harm, including embolism.[5]

Reported risks include infection or abscess, rectal ulceration, perforation, fistula, necrosis and embolism. Prior pelvic radiotherapy may increase fistula risk. PEG sensitivity and, for Vue, sensitivity to its iodine-containing material require individual assessment; the manufacturer states that these populations have not been studied.[3]

A history of spacer placement should therefore be available when evaluating pain, bleeding, infection, new urinary/rectal symptoms or a suspected post-radiation fistula. See Radiation Tissue Effects and Rectovesical Fistula.

References​

1. FDA. SpaceOAR Vue System, K260119. February 10, 2026. Clearance, indications and device summary.

2. Boston Scientific. SpaceOAR Vue System Hydrogel Spacers. Current device description, accessed September 12, 2026. Manufacturer product information.

3. Boston Scientific. SpaceOAR Hydrogel Important Safety Information. Accessed September 12, 2026. Manufacturer safety information.

4. Hamstra DA, Mariados N, Sylvester J, et al. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys. 2017;97:976–985. doi:10.1016/j.ijrobp.2016.12.024.

5. Boston Scientific. Urgent Field Safety Notice: SpaceOAR and SpaceOAR Vue IFU Update. February 24, 2022, including Appendix 1. Manufacturer notice hosted by Swissmedic.